

Initial Prior Authorization States Mandate PANDAS PANS Traditional

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
Abilify	aripiprazole	oral only
Abilify Mycite	aripiprazole	all products
Adderall	amphetamine- dextroamphetamine	all products
Adzenys	amphetamine	all products
Aptensio	methylphenidate	all products
aripiprazole ODT (brand unavailable)	aripiprazole	orally disintegrating tablets (ODT)
Arynta	lisdexamfetamine	all products
Atoncy	atomoxetine	all products
Azstarys	serdexmethylphenidate/ dexmethylphenidate	all products
Bysanti	milsaperidone	all products
Caplyta	lumateperone	all products
clonidine extended-release (brand unavailable)	clonidine extended-release	all products
Cobenfy	xanomeline/trospium chloride	all products
Concerta	methylphenidate	all products

Brand Name	Generic Name	Dosage Form
Cotempla	methylphenidate	all products
Daytrana	methylphenidate	all products
Desoxyn	methamphetamine	all products
Dexedrine	dextroamphetamine	all products
dextroamphetamine (all other brands)	dextroamphetamine	all products
Dyanavel	amphetamine	all products
Evekeo	amphetamine	all products
Fanapt	iloperidone	all products
Focalin	dexmethylphenidate	all products
Intuniv	guanfacine extended-release	all products
Invega	paliperidone	oral only
Jornay	methylphenidate	all products
Latuda	lurasidone	all products
Lybalvi	olanzapine and samidorphan	all products
Methylin	methylphenidate	all products
methylphenidate (all other brands)	methylphenidate	all products
Mezofy	aripiprazole	all products
Mydayis	amphetamine-dextroamphetamine	all products
Onyda XR	clonidine extended-release	all products
Opipza	aripiprazole	all products
ProCentra	dextroamphetamine	all products
Qelbree	viloxazine	all products
QuilliChew	methylphenidate	all products
Quillivant	methylphenidate	all products
Relexxii	methylphenidate	all products
Rexulti	brexpiprazole	all
Ritalin	methylphenidate	all products
Saphris	asenapine	all products
Secuado	asenapine	all products
Strattera	atomoxetine	all products

Brand Name	Generic Name	Dosage Form
Vraylar	cariprazine	all
Vyvanse	lisdexamfetamine	all products
Xelstrym	dextroamphetamine	all products
Zenzedi	dextroamphetamine	all products

Indications

FDA-approved Indications

Abilify

Abilify (aripiprazole) Tablets are indicated for the treatment of:

- Schizophrenia
- Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
- Adjunctive Treatment of Major Depressive Disorder
- Irritability Associated with Autistic Disorder
- Treatment of Tourette's Disorder

Abilify Mycite

Abilify Mycite, a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion, is indicated for the:

- Treatment of adults with schizophrenia.
- Treatment of bipolar I disorder
 - Acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate.
 - Maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate.
- Adjunctive treatment of adults with Major Depressive Disorder.

Limitations of Use

- The ability of the Abilify Mycite to improve patient compliance or modify aripiprazole dosage has not been established.
- The use of Abilify Mycite to track drug ingestion in "real-time" or during an emergency is not recommended because detection may be delayed or not occur.

Adderall

Adderall (Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets (Mixed salts of a single entity amphetamine product)) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Adderall XR

Adderall XR is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.

Limitations of Use

The use of Adderall XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Adzenys XR-ODT, Dyanavel XR

These products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of Use

The use of these products is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Aptensio XR

Aptensio XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of Use

The use of Aptensio XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Aripiprazole Oral Solution

Aripiprazole oral solution is indicated for the treatment of:

- Schizophrenia
- Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
- Irritability Associated with Autistic Disorder
- Treatment of Tourette's Disorder

Aripiprazole Orally Disintegrating Tablets

Aripiprazole orally disintegrating tablets are indicated for the treatment of:

- Schizophrenia
- Irritability Associated with Autistic Disorder
- Treatment of Tourette's Disorder

Arynta

Arynta is indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
- Moderate to severe binge eating disorder (BED) in adults.

Limitations of Use

- Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older.
- Arynta is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Arynta for the treatment of obesity have not been established.

Atoncy

Atoncy is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adult and pediatric patients 6 years of age and older. Atoncy is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD.

Azstarys

Azstarys is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.

Limitations of Use

The use of Azstarys is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Bysanti

Bysanti is indicated for the:

- Treatment of schizophrenia in adults.
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Caplyta

Caplyta is indicated for:

- Treatment of schizophrenia in adults.
- Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
- Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

Clonidine Hydrochloride Extended Release

Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

Cobenfy

Cobenfy is indicated for the treatment of schizophrenia in adults.

Concerta

Concerta is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.

Limitations of Use

The use of Concerta is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Cotempla XR-ODT, Daytrana

These products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Limitations of Use

The use of these products is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than in patients 6 years and older at the same dosage.

Desoxyn

Desoxyn is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older.

Dexedrine Spansule

Dexedrine is indicated in:

Narcolepsy

Attention Deficit Disorder with Hyperactivity

As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome.

Limitations of Use

The use of Dexedrine is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Dextroamphetamine Sulfate Tablets, ProCentra, Zenzedi

These products are indicated for:

- Narcolepsy.

- Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Evekeo

Evekeo (amphetamine sulfate tablets, USP) is indicated for:

- Narcolepsy
- Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.
- Exogenous Obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines should be weighed against possible risks inherent in use of the drug.

Fanapt

Fanapt is indicated for:

- Treatment of schizophrenia in adults.
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Focalin

These products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Focalin XR, QuilliChew ER, Quillivant XR

These products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Limitations of Use

The use of these products is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Intuniv

Intuniv is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

Invega

Schizophrenia

Invega (paliperidone) Extended-Release Tablets are indicated for the treatment of schizophrenia.

The efficacy of Invega in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults.

Schizoaffective Disorder

Invega (paliperidone) Extended-Release Tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy.

The efficacy of Invega in schizoaffective disorder was established in two 6-week trials in adults.

Jornay PM

Jornay PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of Use

The use of Jornay PM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Latuda

Latuda is indicated for:

- Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia.
- Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression).
- Adjunctive treatment with lithium or valproate in adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression).

Lybalvi

Lybalvi is indicated for the treatment of:

- Schizophrenia in adults
- Bipolar I disorder in adults
 - Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate
 - Maintenance monotherapy treatment

Metadate CD

Metadate CD is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age.

Limitations of Use

The use of Metadate CD is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Methylin Oral Solution

Methylin is indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older
- Narcolepsy

Methylphenidate Chewable Tablets

Methylphenidate Hydrochloride Chewable Tablets is indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older
- Narcolepsy

Methylphenidate Tablet, Ritalin

These products are indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years and older and adults
- Narcolepsy

Methylphenidate Extended-Release Tablet

Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years and older and adults
- Narcolepsy

Limitations of Use

The use of these products is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Methylphenidate LA, Ritalin LA

These products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), in pediatric patients 6 to 12 years of age.

Limitations of Use

The use of these products is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Methylphenidate Osmotic Extended-Release, Relexxii

These products are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older.

Limitations of Use

The use of these products is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Mezofy

Mezofy is indicated for the treatment of schizophrenia in adult and pediatric patients 13 years and older.

Mydayis

Mydayis is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.

Limitations of Use

Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose, and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite.

Onyda XR

Onyda XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

Opipza

Opipza is indicated for:

- Treatment of schizophrenia in patients ages 13 years and older
- Adjunctive treatment of major depressive disorder (MDD) in adults
- Treatment of irritability associated with autistic disorder in pediatric patients 6 years and older
- Treatment of Tourette's disorder in pediatric patients 6 years and older

Qelbree

Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

Rexulti

Rexulti is indicated for:

- Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults
- Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
- Treatment of agitation associated with dementia due to Alzheimer's disease

Limitations of Use

Rexulti is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease.

Saphris

Saphris is indicated for:

- Schizophrenia in adults
- Bipolar I disorder
 - Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age
 - Adjunctive treatment to lithium or valproate in adults
 - Maintenance monotherapy treatment in adults

Secuado

Secuado is indicated for the treatment of adults with schizophrenia.

Strattera

Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

The efficacy of Strattera Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trials in adults, and one maintenance trial in pediatrics (ages 6 to 15).

Vraylar

Vraylar is indicated for:

- Treatment of schizophrenia in adults and pediatric patients 13 years of age and older.
- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients 10 years of age and older.
- Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients.
- Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patient.

Vyvanse

Vyvanse is indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
- Moderate to severe binge eating disorder (BED) in adults.

Limitations of Use

- The use of Vyvanse is not recommended in pediatric patients with ADHD younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
- Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

Xelstrym

Xelstrym is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

Limitations of Use

The use of Xelstrym is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Compendial Uses

Adderall XR, Adzenys XR-ODT, Aptensio XR, Arynta, Concerta, Cotempla XR-ODT, Daytrana, Desoxyn, Dyanavel XR, Focalin, Focalin XR, Jornay PM, Methylphenidate CD Capsules, Methylphenidate Osmotic Extended-Release, Mydayis, QuilliChew ER, Quillivant XR, Relexxii, Ritalin LA, Vyvanse, Xelstrym.

- Narcolepsy⁵⁷⁻⁶⁰

Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM, Methylin Oral Solution, Methylphenidate, Methylphenidate CD Capsules, Methylphenidate Chewable Tablets, Methylphenidate Extended Release, Methylphenidate Osmotic Extended-Release, QuilliChew ER, Quillivant XR, Relexxii, Ritalin, Ritalin LA

- Cancer-related fatigue^{59,61-62}

Coverage Criteria

The requested drug will be covered with prior authorization when one (1) of the following criteria is met:

- The requested drug is being prescribed to treat one of the following conditions: pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, pediatric acute onset neuropsychiatric syndrome, or autoimmune encephalitis.

- The requested drug is being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines).

Duration of Approval (DOA)

- 6847-A: DOA: 12 months

References

1. Abilify [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; January 2025.
2. Abilify Mycite [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; January 2025.
3. Adderall [package insert]. Parsippany, NJ: Teva Pharmaceuticals; May 2024.
4. Adderall XR [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; September 2025.
5. Adzenys XR-ODT [package insert]. Denver, CO: Neos Therapeutics Brands, LLC; November 2023.
6. Aptensio XR [package insert]. Wilson, NC: Rhodes Pharmaceuticals; September 2025.
7. Aripiprazole orally disintegrating tablet [package insert]. Hauppauge, NY: ScieGen Pharmaceuticals, Inc.; July 2025.
8. Aripiprazole oral solution [package insert]. Piscataway, NJ: Camber Pharmaceuticals; October 2024.
9. Arynta [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. June 2025.
10. Atoncy [package insert]. Parsippany, NJ: Validus Pharmaceuticals LLC; March 2026.
11. Azstarys [package insert]. Cambridge, MA: Corium, LLC; September 2025.
12. Bysanti [package insert]. Washington, D.C.: Vanda Pharmaceuticals Inc.; February 2026.
13. Caplyta [package insert]. Bedminster, NJ: Intra-Cellular Therapies, Inc.; November 2025.
14. Clonidine hydrochloride tablet, extended release [package insert]. Baltimore, MD: Lupin Pharmaceuticals, Inc.; December 2023.
15. Cobenfy [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; January 2026.
16. Concerta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; September 2025.
17. Cotelpla XR-ODT [package insert]. Denver, CO: Neos Therapeutics Brands, LLC.; September 2025.
18. Daytrana [package insert]. Miami, FL: Noven Therapeutics, LLC; September 2025.
19. Desoxyn [package insert]. Tampa, FL: Ajenat Pharmaceuticals, LLC; September 2024.
20. Dexedrine Spansule [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; September 2025.
21. Dextroamphetamine sulfate [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; April 2024.
22. Dyanavel XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; September 2025.
23. Evekeo [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc.; June 2025.
24. Fanapt [package insert]. Washington, D.C.: Vanda Pharmaceuticals Inc.; May 2025.
25. Focalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2023.

26. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2025.
27. Intuniv [package insert]. Cambridge, MA: Takeda Pharmaceuticals America, Inc.; June 2025.
28. Invega [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2025.
29. Jornay PM [package insert]. Stoughton, MA: Collegium Pharmaceutical, Inc.; September 2025.
30. Latuda [package insert]. Marlborough, MA: Sumitomo Pharma America, Inc.; January 2025.
31. Lybalvi [package insert]. Waltham, MA: Alkermes, Inc.; January 2026.
32. Metadate CD [package insert]. Denver, CO: Aytu BioPharma; September 2025.
33. Methylin Solution [package insert]. Florham Park, NJ: Shionogi Inc.; November 2023.
34. Methylphenidate Hydrochloride Chewable Tablets [package insert]. East Brunswick, NJ: Rising Pharma Holdings, Inc.; March 2025.
35. Methylphenidate Hydrochloride Capsule (LA) [package insert]. Princeton, NJ: Sandoz Inc.; September 2025.
36. Methylphenidate Hydrochloride Tablet [package insert]. Piscataway, NJ: Camber Pharmaceuticals, Inc.; August 2025.
37. Methylphenidate Hydrochloride Extended-Release Tablet [package insert]. Webster Groves, MO: SpecGx LLC; October 2025.
38. Methylphenidate Osmotic Extended Release [package insert]. Alpharetta, GA: Trigen Laboratories, LLC; October 2025.
39. Mezofy [package insert]. Seoul, Republic of Korea: CMG Pharmaceutical Co., Ltd.; April 2025.
40. Mydayis [package insert]. Cambridge, MA: Takeda Pharmaceuticals America, Inc.; March 2025.
41. Onyda XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; April 2025.
42. Opipza [package insert]. Xiamen, Fujian, China: Xiamen LP Pharmaceutical Co., Ltd. August 2024.
43. ProCentra [package insert]. Mason, OH: Independence Pharmaceuticals, LLC; May 2025.
44. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; January 2025.
45. QuilliChew ER [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; September 2025.
46. Quillivant XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; September 2025.
47. Relexxii [package insert]. Alpharetta, GA: Vertical Pharmaceuticals, LLC; September 2025.
48. Rexulti [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2025.
49. Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2025.
50. Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2025.
51. Saphris [package insert]. North Chicago, IL: AbbVie Inc.; January 2025.
52. Secuado [package insert]. Miami, Florida: Noven Therapeutics, LLC; January 2025.
53. Strattera [package insert]. Indianapolis, IN: Lilly USA, LLC; January 2022.
54. Vraylar [package insert]. North Chicago, IL: AbbVie Inc.; December 2025.
55. Vyvanse [package insert]. Cambridge, MA: Takeda Pharmaceuticals America, Inc.; September 2025.
56. Xelstrym [package insert]. Miami, FL: Noven Pharmaceuticals, Inc.; September 2025.
57. Zenzedi [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc.; November 2025.
58. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed February 19, 2026.
59. Lexicomp Online, Lexi-Drugs Online Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed February 19, 2026.

60. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 02/19/2026).
61. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.
62. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue. V.2.2024. Available at: www.nccn.org. Accessed October 13, 2025.
63. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009;38(5):650-662.
64. Delaware House Bill 386. August 2018.
65. Illinois House Bill 2721. July 2017; Illinois Senate Bill 101. June 2023.
66. New Hampshire House Bill 224. September 2019.
67. Minnesota Senate Bill 12a. May 2019.
68. Maryland Senate Bill 475. May 2020; Maryland House Bill 820. May 2022.
69. Indiana House Bill 1372. May 2020.
70. Massachusetts Senate No. 2984. December 2020.
71. Arkansas Senate Bill 387. April 2021; Arkansas Senate Bill 639. April 2021; Arkansas Senate Bill 181 and Amended Rule 127. October 2023.
72. Rhode Island H 7503. June 2022.
73. Oregon Senate Bill 628. May 2023.
74. Colorado House Bill 1382. June 2024.
75. California Assembly Bill 2105. September 2024.
76. Virginia H 1641. March 2025.
77. Georgia SB 5. May 2025.
78. Louisiana House Bill 408. June 2025.